|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar
|
|
2
|
Patard JJ, Leray E, Rioux-Leclercq N,
Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani
W, Abbou CC, et al: Prognostic value of histologic subtypes in
renal cell carcinoma: A multicenter experience. J Clin Oncol.
23:2763–2771. 2005. View Article : Google Scholar
|
|
3
|
Motzer RJ, Jonasch E, Agarwal N, Alva A,
Bagshaw H, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello
BA, et al: NCCN guidelines® insights: Kidney cancer,
version 2.2024. J Natl Compr Canc Netw. 22:4–16. 2024. View Article : Google Scholar
|
|
4
|
Mohanty SK, Lobo A and Cheng L: The 2022
revision of the World Health Organization classification of tumors
of the urinary system and male genital organs: Advances and
challenges. Hum Pathol. 136:123–143. 2023. View Article : Google Scholar
|
|
5
|
Jones RJ, Crabb SJ, Linch M, Birtle AJ,
Mcgrane J, Enting D, Stevenson R, Liu K, Kularatne B and Hussain
SA: Systemic anticancer therapy for urothelial carcinoma: UK
oncologists' perspective. Br J Cancer. 130:897–907. 2024.
View Article : Google Scholar
|
|
6
|
Lopez-Beltran A, Cookson MS, Guercio BJ
and Cheng L: Advances in diagnosis and treatment of bladder cancer.
BMJ. 384:e0767432024. View Article : Google Scholar
|
|
7
|
Rouprêt M, Seisen T, Birtle AJ, Capoun O,
Compérat EM, Dominguez-Escrig JL, Andersson IG, Liedberg F,
Mariappan P, Mostafid AH, et al: European association of urology
guidelines on upper urinary tract urothelial carcinoma: 2023
Update. Eur Urol. 84:49–64. 2023. View Article : Google Scholar
|
|
8
|
Wu K, Liu X, Wang Y, Wang X and Li X:
Clinicopathological characteristics and outcomes of synchronous
renal cell carcinoma and urothelial carcinoma: A population-based
analysis. Front Public Health. 10:9943512022. View Article : Google Scholar
|
|
9
|
Qi N, Chen Y, Gong K and Li H: Concurrent
renal cell carcinoma and urothelial carcinoma: Long-term follow-up
study of 27 cases. World J Surg Oncol. 16:162018. View Article : Google Scholar
|
|
10
|
Council L and Hameed O: Differential
expression of immunohistochemical markers in bladder smooth muscle
and myofibroblasts, and the potential utility of desmin,
smoothelin, and vimentin in staging of bladder carcinoma. Mod
Pathol. 22:639–650. 2009. View Article : Google Scholar
|
|
11
|
Olivier M, Hollstein M and Hainaut P: TP53
mutations in human cancers: Origins, consequences, and clinical
use. Cold Spring Harb Perspect Biol. 2:a0010082010. View Article : Google Scholar
|
|
12
|
Borowczak J, Szczerbowski K, Maniewski M,
Zdrenka M, Słupski P, Andrusewicz H, Bysik-Miśkurka J, Rutkiewicz
P, Bodnar M and Szylberg A: The prognostic role of p53 and its
correlation with CDK9 in urothelial carcinoma. Clin Transl Oncol.
25:830–840. 2023. View Article : Google Scholar
|
|
13
|
Vlachou E, Johnson BR, Baraban E, Nadal R
and Hoffman-Censits J: Current advances in the management of
nonurothelial subtypes of bladder cancer. Am Soc Clin Oncol Educ
Book. 44:e4386402024. View Article : Google Scholar
|
|
14
|
Naik M, Rao BV, Challa S, Fonseca D, Sudha
SM, Giridhar A, Sharma R, Raju KVVN and Rao TS: Utility of GATA-3
and associated immunohistochemical markers in the differential
diagnosis of poorly differentiated urothelial carcinoma. J Cancer
Res Ther. 19 (Suppl):S02023. View Article : Google Scholar
|
|
15
|
Zhou J, Yang X, Zhou L, Zhang P and Wang
C: Combined immunohistochemistry for the ‘three 7’ markers (CK7,
CD117, and claudin-7) is useful in the diagnosis of chromophobe
renal cell carcinoma and for the exclusion of mimics: Diagnostic
experience from a single institution. Dis Markers.
2019:47081542019. View Article : Google Scholar
|
|
16
|
Barr ML, Jilaveanu LB, Camp RL, Adeniran
AJ, Kluger HM and Shuch B: PAX-8 expression in renal tumours and
distant sites: A useful marker of primary and metastatic renal cell
carcinoma? J Clin Pathol. 68:12–17. 2014. View Article : Google Scholar
|
|
17
|
Gorbokon N, Baltruschat S, Lennartz M,
Luebke AM, Höflmayer D, Kluth M, Hube-Magg C, Hinsch A, Fraune C,
Lebok P, et al: PAX8 expression in cancerous and non-neoplastic
tissue: A tissue microarray study on more than 17,000 tumors from
149 different tumor entities. Virchows Arch. 485:491–507. 2024.
View Article : Google Scholar
|
|
18
|
Leroy X, Copin MC, Devisme L, Buisine MP,
Aubert JP, Gosselin B and Porchet N: Expression of human mucin
genes in normal kidney and renal cell carcinoma. Histopathology.
40:450–457. 2002. View Article : Google Scholar
|
|
19
|
Yan WX, Cao WR, Zhao J, Zhang W, Wang XL,
Yuan Q and Dang SQ: Clear cell papillary renal cell carcinoma: A
clinicopathologic analysis of 6 cases. Int J Clin Exp Pathol.
8:4595–4599. 2015.
|
|
20
|
Amin MB, Edge SB, Greene FL and Brierley
JD: AJCC cancer staging manual. 8th edition. New York: Springer;
2017
|
|
21
|
Pandey J and Syed W: Renal cancer.
StatPearls [Internet] Treasure Island (FL): StatPearls Publishing;
2024
|
|
22
|
Kaseb H, Leslie SW, Soon-Sutton TL and
Aeddula NR: Bladder cancer. StatPearls Treasure Island: StatPearls
Publishing; 2023
|
|
23
|
Kim HL, Seligson D, Liu X, Janzen N, Bui
MHT, Yu H, Shi T, Belldegrun AS, Horvath S and Figlin RA: Using
tumor markers to predict the survival of patients with metastatic
renal cell carcinoma. J Urol. 173:1496–1501. 2005. View Article : Google Scholar
|
|
24
|
Gailey MP and Bellizzi AM:
Immunohistochemistry for the novel markers glypican 3, PAX8, and
p40 (ΔNp63) in squamous cell and urothelial carcinoma. Am J Clin
Pathol. 140:872–880. 2013. View Article : Google Scholar
|
|
25
|
Queipo FJ, Unamunzaga GM, Negro BF,
Fuertes SG, Cortés MÁ, Tejedor EC, Mañas CMB, Ariño AB, Sjödahl G
and Beorlegui C: Immunohistochemistry subtyping of urothelial
carcinoma is feasible in the daily practice. Virchows Arch.
481:191–200. 2022. View Article : Google Scholar
|
|
26
|
Huang J and Zhang X: Chinese guidelines
for diagnosis and treatment of urology and andrology diseases (2022
edition). 2022.
|
|
27
|
Motzer RJ, Michaelson MD, Redman BG, Hudes
GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE,
et al: Activity of SU11248, a multitargeted inhibitor of vascular
endothelial growth factor receptor and platelet-derived growth
factor receptor, in patients with metastatic renal cell carcinoma.
J Clin Oncol. 24:16–24. 2006. View Article : Google Scholar
|
|
28
|
Guo J, Ma J, Sun Y, Qin S, Ye D, Zhou F,
He Z, Sheng X, Bi F, Cao D, et al: Chinese guidelines on the
management of renal cell carcinoma (2015 edition). Chin Clin Oncol.
5:122016. View Article : Google Scholar
|
|
29
|
Ye D, Liu J, Zhou A, Zou Q, Li H, Fu C, Hu
H, Huang J, Zhu S, Jin J, et al: Tislelizumab in Asian patients
with previously treated locally advanced or metastatic urothelial
carcinoma. Cancer Sci. 112:305–313. 2021. View Article : Google Scholar
|
|
30
|
Liu Y, Liu Q, Huang L, Ren X, Huang J and
Feng YF: A programmed death receptor-1 inhibitor-Tislelizumab. Clin
Med J. 20:37–42. 2022.(In Chinese).
|
|
31
|
Hong Y, Feng Y, Sun H, Zhang B, Wu H, Zhu
Q, Li Y, Zhang T, Zhang Y, Cui X, et al: Tislelizumab uniquely
binds to the CC' loop of PD-1 with slow-dissociated rate and
complete PD-L1 blockage. FEBS Open Bio. 11:782–792. 2021.
View Article : Google Scholar
|
|
32
|
Yokoyama I, Berman E, Rickert RR and
Bastidas J: Simultaneous occurrence of renal cell adenocarcinoma
and urothelial carcinoma of the renal pelvis in the same kidney
diagnosed by preoperative angiography. Cancer. 48:2762–2766. 1981.
View Article : Google Scholar
|
|
33
|
Oka H, Kobayashi S, Kobayashi T, Shugino
Y, Matsui Y, Fujikawa K, Iwamura H, Hukuzawa S, Soeda A and
Takeuchi H: Multiple primary cancers limited to the urological
field. Hinyokika Kiyo. 47:405–409. 2001.(In Japanese).
|
|
34
|
Srinath N, Dinesh US and Sharma GP: A case
of synchronous renal cell carcinoma (Rt) and transitional cell
carcinoma urinary bladder. Med J Armed Forces India. 62:190–191.
2011. View Article : Google Scholar
|
|
35
|
Zhang H, Ye D, Yao X, Zhang S, Dai B, Shen
Y, Zhu Y, Zhu Y, Shi G, et al: Clinical analysis of multiple
primary malignant tumors and concurrent renal cell carcinoma. J
Army Med Univ. 31:1261–1263. 2009.(In Chinese).
|
|
36
|
Rotellini M, Fondi C, Paglierani M,
Stomaci N and Raspollini MR: Clear cell carcinoma of the bladder in
a patient with a earlier clear cell renal cell carcinoma: A case
report with morphologic, immunohistochemical, and cytogenetical
analysis. Appl Immunohistochem Mol Morphol. 18:396–399. 2010.
View Article : Google Scholar
|
|
37
|
Smith MT, Taylor FD, Gianakopoulus WP and
Brown RR: Two separate synchronous primary genitourinary tumors.
Rev Urol. 14:104–107. 2012.
|
|
38
|
Zhu Q, Gu J, Zhang Y, Shi J, Sun F, Shen
J, Yang Y and Wang N: Clinical analysis of 21 cases of multiple
primary cancers associated with bladder cancer in elderly patients.
Chin J Clin Oncol. 39:993–996. 2012.(In Chinese).
|
|
39
|
Djafari AA, Moradi A, Rahnama H and
Rahavian A: The first case report of synchronous primary papillary
type 2 renal cell carcinoma of kidney and transitional cell
carcinoma of bladder. Urol Case Rep. 37:1016012021. View Article : Google Scholar
|
|
40
|
Dieckmann KP and Nekarda H: Triple
malignancy of the genitourinary tract. Int Urol Nephrol.
20:485–488. 1988. View Article : Google Scholar
|
|
41
|
Harima M, Narita K, Kobayakawa H, Tsujino
T, Yamamoto S, Fukushima S and Kishimoto T: A case of synchronous
triple primary cancers of prostate, kidney and bladder. Hinyokika
Kiyo. 44:675–678. 1998.(In Japanese).
|
|
42
|
Takada T, Honda M, Momohara C, Komori K
and Fujioka H: Synchronous triple urogenital cancer (renal cancer,
bladder cancer, prostatic cancer): A case report. Hinyokika Kiyo.
48:239–242. 2002.(In Japanese).
|
|
43
|
Satoh H, Momma T, Saito S and Hirose S: A
case of synchronous triple primary carcinomas of the kidney,
bladder and prostate. Hinyokika Kiyo. 49:261–264. 2003.(In
Japanese).
|
|
44
|
Arikan-Sengul C, Pehlivan Y, Sevinc A,
Karakok M, Kalender ME and Camci C: A case of metachronous triple
primary urogenital cancer: Urinary bladder, prostate, and renal
cancer. Onkologie. 32:122–124. 2009.
|
|
45
|
Nishikawa K, Soga N, Kato M, Masui S,
Hasegawa Y, Yamada Y, Kise H, Arima K and Sugimura Y: Case of
bladder cancer following adjuvant external beam radiation for
prostate cancer. Hinyokika Kiyo. 55:39–41. 2009.(In Japanese).
|
|
46
|
Pérez MPM, Bazán AA, Dorrego JMA, Herrero,
Ledo JC and de la Peña Barthel J: Simultaneous cystectomy and
nephroureterectomy due to synchronous upper urinary tract tumors
and invasive bladder cancer: Open and laparoscopic approaches. Curr
Urol. 6:76–81. 2012. View Article : Google Scholar
|
|
47
|
Tiwari P, Tripathi A, Bansal P, Vijay M,
Gupta A and Kundu AK: Synchronous primary cancers of urinary
bladder and kidney and prostate. Saudi J Kidney Dis Transpl.
23:786–789. 2012. View Article : Google Scholar
|
|
48
|
Okumura A, Tsuritani S, Takagawa K and
Fuse H: Case of heterochronous triple urogenital cancer (renal cell
carcinoma, bladder cancer, prostatic cancer). Nihon Hinyokika
Gakkai Zasshi. 104:702–705. 2013.(In Japanese).
|
|
49
|
Kurose H, Ueda K, Nakiri M, Matsuo M,
Suekane S and Igawa T: Synchronous primary triple urogenital
malignant tumors of kidney, prostate and bladder. Urol Case Rep.
33:1012772020. View Article : Google Scholar
|
|
50
|
Zhang G, Liao H, Liu L, Tang D and Zhang
F: A case report of synchronous triple cancers in the urinary and
male reproductive system. Chin J Urol. 44:861–862. 2023.(In
Chinese).
|
|
51
|
Kinbara H, Suzuki S, Nakano S, Yamakawa K,
Hioki T, Okabe S, Sugimura Y, Tajima K, Tochigi H and Kawamura J: A
case of renal cell carcinoma and bladder carcinoma associated with
von Hippel-Lindau disease. Hinyokika Kiyo. 36:823–826. 1990.(In
Japanese).
|
|
52
|
Nakano S, Suzuki S, Kinbara H, Maeda Y,
Yanagawa M, Tajima K, Tochigi H, Kawamura J, Hounoki S and Yamamoto
I: A case of double cancer: Renal cell carcinoma and transitional
cell carcinoma of urinary bladder. Hinyokika Kiyo. 36:831–835.
1990.(In Japanese).
|
|
53
|
Soda T, Nishimura K, Kobayashi Y, Kato T,
Tokugawa S, Kishikawa H, Ihara H and Ichikawa Y: A case of
synchronous contralateral renal cell carcinoma and urothelial
carcinoma. Hinyokika Kiyo. 55:491–494. 2009.(In Japanese).
|
|
54
|
Ando M, Arisawa C and Okano T: A case of
renal cell carcinoma associated with synchronous contralateral
renal pelvic cancer and bladder tumor. Int J Urol. 3:310–312. 1996.
View Article : Google Scholar
|
|
55
|
Lian Y, Wang D, Chen Q, Zhang Y, Shangguan
Z, Jiang M, Hu K and Hao W: A clinical analysis for 9 cases of
multiple primary malignant neoplasms associated with renal cell
carcinoma. Oncol Prog. 18:815–818. 2020.(In Chinese).
|
|
56
|
Tsujimura A, Takahara S and Koide T: A
case of synchronous ipsilateral renal cell carcinoma and
transitional cell carcinoma. Hinyokika Kiyo. 37:1303–1306. 1991.(In
Japanese).
|
|
57
|
Chuang HC, Chuang CK and Ng KF:
Simultaneous development of renal cell carcinoma and multifocal
urothelial carcinoma. Chang Gung Med J. 31:515–519. 2008.
|
|
58
|
Morikawa Y, Shiomi K, Ishihara Y and
Matsuura N: Triple primary cancers involving kidney, urinary
bladder, and liver in a dye worker. Am J Ind Med. 31:44–49. 1997.
View Article : Google Scholar
|
|
59
|
Kamota S, Harabayashi T, Suzuki S,
Takeyama Y, Mitsui T, Mouri G, Hashimoto A, Nakamura M, Shinohara
N, Nonomura K and Koyanagi T: Ureteral and bladder metastases of
renal cell carcinoma following synchronous renal cell carcinoma and
bladder cancer; a case report. Nihon Hinyokika Gakkai Zasshi.
94:705–708. 2003.(In Japanese).
|
|
60
|
Gönül II, Cakr A, Sözen S, Ataoglu O and
Alkibay T: A case of tubulocystic carcinoma simultaneously
occurring with clear cell type renal cell carcinoma and
micropapillary urothelial carcinoma of bladder. South Med J.
102:754–757. 2009. View Article : Google Scholar
|
|
61
|
Wang Y, Yu Z, He H, Wang X, Ge H and Xie
X: Cancerization of ureteral inverted papilloma complicated with
ipsilateral renal cell cancer and bladder transitional cell
carcinoma: One case report. J Chin Oncol. 22:691–692. 2016.(In
Chinese).
|
|
62
|
Xu G, Bu S and Wang X: A case report of
four primary malignant tumors. Cancer Res Prev Treat. 46:1141–1142.
2019.(In Chinese).
|
|
63
|
Akan S and Ediz C: A rare association in a
patient with non-muscle invasive bladder cancer: Ureteral
fibroepithelial polyp and ipsilateral renal cell carcinoma: A case
report. J Med Case Rep. 15:4752021. View Article : Google Scholar
|
|
64
|
Mitchell K, El Naili R, Pillai L, Lopez
EM, Riordan J, Marsh W, Luchey A and Hajiran A: Triple threat:
Three primary malignancies simultaneously involving three
genitourinary organs. Case Rep Urol. 2023:32429862023.
|
|
65
|
Huang J, Deng S, Li Q, Li J, Li W, Zhang X
and Xue S: Multiple primary malignancies of the bladder, rectum and
kidney: A case report. Chin J Urol. 44:383–384. 2023.(In
Chinese).
|
|
66
|
Lobo N, Afferi L, Moschini M, Mostafid H,
Porten S, Psutka SP, Gupta S, Smith AB, Williams SB and Lotan Y:
Epidemiology, screening, and prevention of bladder cancer. Eur Urol
Oncol. 5:628–639. 2022. View Article : Google Scholar
|
|
67
|
Dyrskjøt L, Hansel DE, Efstathiou JA,
Knowles MA, Galsky MD, Teoh J and Theodorescu D: Bladder cancer.
Nat Rev Dis Primers. 9:582023. View Article : Google Scholar
|
|
68
|
Aminoltejari K and Black PC: Radical
cystectomy: A review of techniques, developments and controversies.
Transl Androl Urol. 9:3073–3081. 2020. View Article : Google Scholar
|
|
69
|
Khan MS, Gan C, Ahmed K, Ismail AF,
Watkins J, Summers JA, Peacock JL, Rimington P and Dasgupta P: A
single-centre early phase randomised controlled three-arm trial of
open, robotic, and laparoscopic radical cystectomy (CORAL). Eur
Urol. 69:613–621. 2016. View Article : Google Scholar
|
|
70
|
Dindo D, Demartines N and Clavien PA:
Classification of surgical complications: A new proposal with
evaluation in a cohort of 6336 patients and results of a survey.
Ann Surg. 240:205–213. 2004. View Article : Google Scholar
|
|
71
|
Griffiths G, Hall R, Sylvester R, Raghavan
D and Parmar MK: International phase III trial assessing
neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy
for muscle-invasive bladder cancer: long-term results of the BA06
30894 trial. J Clin Oncol. 29:2171–2177. 2011. View Article : Google Scholar
|
|
72
|
Advanced Bladder Cancer (ABC)
Meta-analysis Collaboration, . Neoadjuvant chemotherapy in invasive
bladder cancer: update of a systematic review and meta-analysis of
individual patient data advanced bladder cancer (ABC) meta-analysis
collaboration. Eur Urol. 48:202–206. 2005. View Article : Google Scholar
|
|
73
|
van der Heijden MS, Sonpavde G, Powles T,
Necchi A, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P,
Bedke J, et al: Nivolumab plus gemcitabine-cisplatin in advanced
urothelial carcinoma. N Engl J Med. 389:1778–1789. 2023. View Article : Google Scholar
|
|
74
|
von der Maase H, Hansen SW, Roberts JT,
Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A,
Lippert CM, et al: Gemcitabine and cisplatin versus methotrexate,
vinblastine, doxorubicin, and cisplatin in advanced or metastatic
bladder cancer: Results of a large, randomized, multinational,
multicenter, phase III study. J Clin Oncol. 41:3881–3890. 2023.
View Article : Google Scholar
|
|
75
|
Powles T, Park SH, Voog E, Caserta C,
Valderrama BP, Gurney H, Kalofonos H, Radulović S, Demey W, Ullén
A, et al: Avelumab maintenance therapy for advanced or metastatic
urothelial carcinoma. N Engl J Med. 383:1218–1230. 2020. View Article : Google Scholar
|
|
76
|
Massari F, Santoni M, Takeshita H, Okada
Y, Tapia JC, Basso U, Maruzzo M, Scagliarini S, Büttner T,
Fornarini G, et al: Global real-world experiences with
pembrolizumab in advanced urothelial carcinoma after platinum-based
chemotherapy: The ARON-2 study. Cancer Immunol Immunother.
73:1062024. View Article : Google Scholar
|
|
77
|
Chang SS, Bochner BH, Chou R, Dreicer R,
Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, et
al: Treatment of non-metastatic muscle-invasive bladder cancer:
AUA/ASCO/ASTRO/SUO guideline. J Urol. 198:552–559. 2017. View Article : Google Scholar
|
|
78
|
Powles T, Bellmunt J, Comperat E, De
Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A,
Shariat SF, et al: ESMO clinical practice guideline interim update
on first-line therapy in advanced urothelial carcinoma. Ann Oncol.
35:485–490. 2024. View Article : Google Scholar
|
|
79
|
Benjamin DJ, Rezazadeh KA and Prasad V:
The overall survival benefit in EV-302: Is enfortumab vedotin plus
pembrolizumab the new frontline standard of care for metastatic
urothelial carcinoma? Eur Urol Oncol. 7:313–315. 2024. View Article : Google Scholar
|
|
80
|
Cirillo L, Innocenti S and Becherucci F:
Global epidemiology of kidney cancer. Nephrol Dial Transplant.
39:920–928. 2024. View Article : Google Scholar
|
|
81
|
Deng J, Tu S, Li L, Li G and Zhang Y:
Diagnostic, predictive and prognostic molecular biomarkers in clear
cell renal cell carcinoma: A retrospective study. Cancer Rep
(Hoboken). 7:e21162024. View Article : Google Scholar
|
|
82
|
Safiri S, Hassanzadeh K, Jolfayi AG,
Mousavi SE, Asghari KM, Nejadghaderi SA, Naghdi-Sedeh N, Noori M,
Sullman MJM, Collins GS and Kolahi AA: Kidney cancer in the Middle
East and North Africa region: A 30-year analysis (1990–2019). Sci
Rep. 14:137102024. View Article : Google Scholar
|
|
83
|
Hunt JD, van der Hel OL, Mcmillan GP,
Boffetta P and Brennan P: Renal cell carcinoma in relation to
cigarette smoking: Meta-analysis of 24 studies. Int J Cancer.
114:101–108. 2005. View Article : Google Scholar
|
|
84
|
Chow WH, Dong LM and Devesa SS:
Epidemiology and risk factors for kidney cancer. Nat Rev Urol.
7:245–257. 2010. View Article : Google Scholar
|
|
85
|
Roskoski R Jr: Combination immune
checkpoint and targeted protein kinase inhibitors for the treatment
of renal cell carcinomas. Pharmacol Res. 203:1071812024. View Article : Google Scholar
|
|
86
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar
|
|
87
|
Goswamy R, Kalemoglu E, Master V and Bilen
MA: Perioperative systemic treatments in renal cell carcinoma.
Front Oncol. 14:13621722024. View Article : Google Scholar
|
|
88
|
Gao B, Gorgen ARH, Bhatt R, Tano ZE,
Morgan KL, Vo K, Zarandi SS, Ali SN, Jiang P, Patel RM, et al:
Avoiding ‘Needless’ nephrectomy: What is the role of small renal
mass biopsy in 2024? Urol Oncol. 42:236–244. 2024. View Article : Google Scholar
|
|
89
|
Johnson DC, Vukina J, Smith AB, Meyer AM,
Wheeler SB, Kuo TM, Tan HJ, Woods ME, Raynor MC, Wallen EM, et al:
Preoperatively misclassified, surgically removed benign renal
masses: A systematic review of surgical series and United States
population level burden estimate. J Urol. 193:30–35. 2015.
View Article : Google Scholar
|
|
90
|
Warren S: Multiple primary malignant
tumors, a survey of the literature and a statistical study. Am J
Cancer. 16:1358–1414. 1932.
|
|
91
|
Vogt A, Schmid S, Heinimann K, Frick H,
Herrmann C, Cerny T and Omlin A: Multiple primary tumours:
Challenges and approaches, a review. ESMO Open. 2:e0001722017.
View Article : Google Scholar
|
|
92
|
Gul ZG, Liaw CW and Mehrazin R: Gender
differences in incidence, diagnosis, treatments, and outcomes in
clinically localized bladder and renal cancer. Urology.
151:176–181. 2021. View Article : Google Scholar
|
|
93
|
Czene K and Hemminki K: Familial papillary
renal cell tumors and subsequent cancers: A nationwide
epidemiological study from Sweden. J Urol. 169:1271–1275. 2003.
View Article : Google Scholar
|
|
94
|
Rabbani F, Reuter VE, Katz J and Russo P:
Second primary malignancies associated with renal cell carcinoma:
Influence of histologic type. Urology. 56:399–403. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Antonelli A, Calza S, Arrighi N, Zani D,
Corti S, Cozzoli A, Zanotelli T, Cunico SC and Simeone C: Clinical
features and prognosis of patients with renal cancer and a second
malignancy. Urol Oncol. 30:294–300. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Lonati C, Simeone C, Suardi N, Spiess PE,
Necchi A and Moschini M: Genitourinary manifestations of Lynch
syndrome in the urological practice. Asian J Urol. 9:443–450. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Umar A, Boland CR, Terdiman JP, Syngal S,
de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ,
Hamelin R, et al: Revised Bethesda guidelines for hereditary
nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite
instability. J Natl Cancer Inst. 96:261–268. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Nassour AJ, Jain A, Hui N, Siopis G,
Symons J and Woo H: Relative risk of bladder and kidney cancer in
lynch syndrome: Systematic review and meta-analysis. Cancers
(Basel). 15:5062023. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Wu KY, Cheong IS, Lai JN, Hu CY, Hung KC,
Chen YT, Chiu LT, Tsai HT, Jou YC, Tzai TS and Tsai YS: Risk of
secondary primary malignancies in survivors of upper tract
urothelial carcinoma: A nationwide population-based analysis.
Cancer Epidemiol. 89:1025362024. View Article : Google Scholar : PubMed/NCBI
|
